Global big pharmas are going on a shopping spree for companies and technology, while in some cases trimming their own R&D operations. Their dependency on partnerships and acquisitions to enrich pipelines is rising as more and more new approvals increasingly stem from activities originally conducted by smaller companies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?